CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Venture Capital Gain (Loss), Net
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Venture Capital Gain (Loss), Net of -$3.28 million for the 3-month period ending 2023-04-01, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:VentureCapitalGainsLossesNet · last filed 2023-05-11
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. venture capital gain (loss), net for the quarter ending 2023-04-01 was -$3.28M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. venture capital gain (loss), net for the quarter ending 2022-09-24 was $3.45M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. venture capital gain (loss), net for the quarter ending 2022-06-25 was -$9.61M, a 197.99% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. venture capital gain (loss), net for the quarter ending 2022-03-26 was -$13.90M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. venture capital gain (loss), net for fiscal 2021 was -$24.20M, a 124.10% decline from fiscal 2020.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. venture capital gain (loss), net for fiscal 2020 was $100.40M, a 385.02% increase from fiscal 2019.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. venture capital gain (loss), net for fiscal 2019 was $20.70M, a 30.19% increase from fiscal 2018.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. venture capital gain (loss), net for fiscal 2018 was $15.90M, a 30.47% decline from fiscal 2017.
| Period end | Venture Capital Gain (Loss), Net 3 month | Venture Capital Gain (Loss), Net 6 month | Venture Capital Gain (Loss), Net 9 month | Venture Capital Gain (Loss), Net 12 month | Venture Capital Gain (Loss), Net 12 month as first filed |
|---|---|---|---|---|---|
| 2023-04-01 | -$3.28M 10-Q · filed 2023-05-11 | ||||
| 2022-09-24 | $3.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$6.17M derived: sum of 2 quarters · filed 2022-11-02 | -$20.07M 10-Q · filed 2022-11-02 | -$26.99M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-06-25 | -$9.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$23.52M 10-Q · filed 2022-08-03 | -$30.44M derived: sum of 3 quarters · filed 2023-05-11 | -$40.80M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-03-26 | -$13.90M 10-Q · filed 2023-05-11 | -$20.83M derived: sum of 2 quarters · filed 2023-05-11 | -$31.19M derived: sum of 3 quarters · filed 2023-05-11 | -$21.38M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-25 | -$6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | -$17.29M derived: sum of 2 quarters · filed 2022-11-02 | -$7.48M derived: sum of 3 quarters · filed 2022-11-02 | -$24.20M 10-K · filed 2022-02-16 | |
| 2021-09-25 | -$10.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$558.00K derived: sum of 2 quarters · filed 2022-11-02 | -$17.28M 10-Q · filed 2022-11-02 | $50.90M derived: sum of 4 quarters · filed 2022-11-02 | |
| 2021-06-26 | $9.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$6.91M 10-Q · filed 2022-08-03 | $61.26M derived: sum of 3 quarters · filed 2022-08-03 | $81.61M derived: sum of 4 quarters · filed 2022-08-03 | |
| 2021-03-27 | -$16.72M 10-Q · filed 2022-05-04 | $51.45M derived: sum of 2 quarters · filed 2022-05-04 | $71.81M derived: sum of 3 quarters · filed 2022-05-04 | $95.72M derived: sum of 4 quarters · filed 2022-05-04 | |
| 2020-12-26 | $68.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $88.52M derived: sum of 2 quarters · filed 2022-02-16 | $112.44M derived: sum of 3 quarters · filed 2022-02-16 | $100.40M 10-K · filed 2022-02-16 | |
| 2020-09-26 | $20.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $44.26M derived: sum of 2 quarters · filed 2021-11-03 | $32.23M 10-Q · filed 2021-11-03 | $47.20M derived: sum of 4 quarters · filed 2022-02-16 | |
| 2020-06-27 | $23.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $11.88M 10-Q · filed 2021-08-04 | $26.85M derived: sum of 3 quarters · filed 2022-02-16 | $26.25M derived: sum of 4 quarters · filed 2022-02-16 | |
| 2020-03-28 | -$12.04M 10-Q · filed 2021-05-04 | $2.94M derived: sum of 2 quarters · filed 2022-02-16 | $2.34M derived: sum of 3 quarters · filed 2022-02-16 | -$1.91M derived: sum of 4 quarters · filed 2022-02-16 | |
| 2019-12-28 | $14.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $14.38M derived: sum of 2 quarters · filed 2022-02-16 | $10.13M derived: sum of 3 quarters · filed 2022-02-16 | $20.70M 10-K · filed 2022-02-16 | $20.71M 10-K · filed 2020-02-11 |
| 2019-09-28 | -$597.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$4.85M derived: sum of 2 quarters · filed 2020-10-29 | $5.72M 10-Q · filed 2020-10-29 | -$1.14M derived: sum of 4 quarters · filed 2021-02-17 | |
| 2019-06-29 | -$4.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $6.32M 10-Q · filed 2020-08-05 | -$539.00K derived: sum of 3 quarters · filed 2021-02-17 | $4.84M derived: sum of 4 quarters · filed 2021-02-17 | |
| 2019-03-30 | $10.57M 10-Q · filed 2020-05-07 | $3.71M derived: sum of 2 quarters · filed 2021-02-17 | $9.09M derived: sum of 3 quarters · filed 2021-02-17 | $20.02M derived: sum of 4 quarters · filed 2021-02-17 | |
| 2018-12-29 | -$6.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$1.49M derived: sum of 2 quarters · filed 2021-02-17 | $9.45M derived: sum of 3 quarters · filed 2021-02-17 | $15.90M 10-K · filed 2021-02-17 | $15.93M 10-K · filed 2019-02-13 |
| 2018-09-29 | $5.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $16.31M derived: sum of 2 quarters · filed 2019-11-06 | $22.76M 10-Q · filed 2019-11-06 | $33.31M derived: sum of 4 quarters · filed 2020-02-11 | |
| 2018-06-30 | $10.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $17.39M 10-Q · filed 2019-07-31 | $27.93M derived: sum of 3 quarters · filed 2020-02-11 | $33.56M derived: sum of 4 quarters · filed 2020-02-11 | |
| 2018-03-31 | $6.45M 10-Q · filed 2019-05-07 | $17.00M derived: sum of 2 quarters · filed 2020-02-11 | $22.63M derived: sum of 3 quarters · filed 2020-02-11 | $25.21M derived: sum of 4 quarters · filed 2020-02-11 | |
| 2017-12-30 | $10.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-11 | $16.18M derived: sum of 2 quarters · filed 2020-02-11 | $18.76M derived: sum of 3 quarters · filed 2020-02-11 | $22.87M 10-K · filed 2020-02-11 | |
| 2017-09-30 | $5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $8.22M derived: sum of 2 quarters · filed 2018-11-07 | $12.32M 10-Q · filed 2018-11-07 | ||
| 2017-07-01 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $6.69M 10-Q · filed 2018-08-08 | |||
| 2017-04-01 | $4.10M 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | $10.28M 10-K · filed 2019-02-13 | ||||
| 2015-12-26 | $3.82M 10-K · filed 2018-02-13 | ||||
| 2014-12-27 | $9.30M 10-K · filed 2017-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |